Target intelligence / Profile preview

Galectin-10 (Gal-10)

Target
Gal-10
Molecular classification
Lectin, Enzyme (lysophospholipase), Beta-galactoside-binding protein
01

Overview

Galectin-10 is a member of the galectin family, encoded by the CLC gene, and is the principal constituent of Charcot-Leyden crystals found in eosinophilic inflammatory conditions such as asthma[1][3][4]. It functions as a lectin and lysophospholipase, hydrolyzing lysophosphatidylcholine, and participates in immune regulation, notably within regulatory T-cells. Galectin-10 forms homodimers with a unique structure distinct from other prototype galectins and is found in the cytoplasm and extracellular space of eosinophils and basophils[1][4]. It interacts with tubulin α-1B and may have low-affinity carbohydrate binding activity. Disruption of CLCs by reduced glutathione or anti-Gal-10 antibodies suggests Galectin-10 is a viable target for novel therapies for eosinophilic diseases, though targeting must carefully balance immune functions[1][4].

Other names
Charcot-Leyden crystal proteinCLCLGALS10LGALS10AEosinophil lysophospholipaseLysolecithin acylhydrolaseGalectin 10lectin, galactoside-binding, soluble, 10
02

Mechanism of action

Reduced glutathione chemically modifies Gal-10 (Cys57), disrupting CLCs. Colchicine targets Gal-10-tubulin interaction, preventing crystal formation.

03

Biological functions

Carbohydrate bindingRegulation of immune responses (notably Treg suppressive function)Hydrolysis of lysophosphatidylcholineFormation of Charcot-Leyden crystals in eosinophils
04

Disease associations

Inflammation (asthma, eosinophilic disorders)Myeloid leukemiaImmunological dysregulation
05

Safety considerations

Potential off-target effects of agents disrupting Galectin-10/CLC (e.g., broad glycan binding, immune modulation)Therapeutic targeting risks disturbing normal immune regulation
06

Interacting drugs

Reduced glutathione (GSH)

1 more in the full profile.

07

Biomarkers

Charcot-Leyden crystals are biomarkers of eosinophilic inflammation (in tissues, sputa, e.g. asthma)Galectin-10 levels mark Treg cell suppressive function

Beyond the preview

Go deeper on Galectin-10 (Gal-10).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Galectin-10 (Gal-10).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call